Dan Anders shared Tower’s experience on a possible trend to shift drug spend to ancillary services and alternative treatment (like acupuncture) and any effect on MSAs with WorkCompCentral’s Elaine Goodman. While another company said its average MSA amount was up 5.1% in 2018, Tower’s data shows a 13% decline in the average CMS-approved MSA. This is mainly due to reductions in prescription drugs, Anders said. And, although 66% of Tower’s MSAs were approved with no pharmacy allocation, Tower has not seen an increased allocation for non-pharmacy treatment. See more (subscription required) here.